MOPP #5 in Advanced Hodgkin's Disease

Bleomycin in combination with MOPP in the management of advanced Hodgkin's disease: A Southwest Oncology Group experience. In: Bleomycin Chemotherapy, BI Sikic, M Rozencweig, SK Carter, eds.

C Coltman, Jr.;SE Jones;PN Grozea;EJ DePersio;DO Dixon Academic Press Inc., Harcourt Brace Jovanovitch New York. Chap ii, pp. 137-153

Comparison of Adriamycin-containing chemotherapy (MOP- BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group study

SE Jones;A Haut;JK Weick;HE Wilson;P Grozea;CJ Fabian;E McKelvey;GE Byrne Jr;R Hartsock;DO Dixon;CA Coltman Jr Cancer 51:1339-1347

Combined modality treatment of advanced Hodgkin's disease: Southwest Oncology Group studies In:

CA Coltman Jr;E Frei III;E Montague;PN Grozea;EJ DePersio;CJ Fabian;CM Mansfield;SE Jones;DO Dixon In: Management of Advanced Cancer P Periman, E Savlov eds. Masson Publishing USA 79-111

Mistaken clinical and pathologic diagnosis of Hodgkin's Disease: A Southwest Oncology Group study

TP Miller;GE Byrne;SE Jones Cancer Treat Rep 66:645-651

Surgical restaging of Hodgkin's disease

GE Goodman;SE Jones;HV Villar;ME Silverstien;L Dabich;SR Newcome;the Southwest Cancer Treat Rep 66: 751-757

Improved remission induction chemotherapy for patients with advanced Hodgkin's disease: A Southwest Oncology Group study

SE Jones;RJ Fisher;J Jones;CA Coltman Jr ASCO #C-571

Comparison of 3 combination drug programs for advanced Hodgkin's disease (HD): A preliminary report of the Southwest Oncology Group (SWOG) MOPP #5 study

SE Jones;CA Coltman Jr AACR 19:333

Lymphoma pathology repository review in the Southwest Oncology Group (SWOG)

SE Jones;JJ Butler;GE Byrne Jr;CA Coltman Jr ASCO 17:249 (#C-49)